bms-986178
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 16, 2016 (NCT02737475)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297705 ↗
Also known as
- bms-986178
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03831295 | Phase 1 | Mar 13, 2019 | Bristol-Myers Squibb, Stanford University |
| NCT03410901 | Phase 1 | Apr 9, 2018 | National Cancer Institute (NCI), Stanford University |
| NCT02737475 | Phase 1/Phase 2 (Phase 2) | Jun 16, 2016 | Bristol-Myers Squibb |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 1 | 2 | 2016 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1